Certolizumab pegol for treating axial spondyloarthritis

References

• Sieper, J., et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009;68(Suppl 2):ii1–44.
   PubMedGoogle Scholar
• Rudwaleit, M., et al. The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68(6):777–783.
   PubMed Web of Science ®Google Scholar
• Oldroyd, J., et al. Ankylosing spondylitis patients commencing biologic therapy have high baseline levels of comorbidity: a report from the Australian rheumatology association database. Int J Rheumatol. 2009;2009:268569.
   PubMedGoogle Scholar
• Migliore, A., et al. Indirect comparison between subcutaneous biologic agents in ankylosing spondylitis. Clin Drug Investig. 2015;35(1):23–29.
   PubMed Web of Science ®Google Scholar
• Breban, M., et al. Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study. Rheumatology (Oxford). 2002;41(11):1280–1285.
   PubMed Web of Science ®Google Scholar
• Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun. 2010;11:180–210.
   PubMedGoogle Scholar
• McCormack PL, Wellington K. Etanercept: in ankylosing spondylitis. BioDrugs. 2004;18(3):199–205; discussion 206
   PubMed Web of Science ®Google Scholar
• Ward M.M., et al. American college of rheumatology/spondylitis association of America/Spondyloarthritis research and treatment network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2016;68(2):282–298.
   PubMed Web of Science ®Google Scholar
• Landewe, R., et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis. 2014;73(1):39–47.
   PubMed Web of Science ®Google Scholar
• UCB Inc. Cimzia (certolizumab pegol): US prescribing information [Internet]. 2016 [cited 2016 May 12]. Available from: http://www.ucb.com/_up/ucb_com_products/documents/CIMZIA_Current_COL_04_2016.pdf
   Google Scholar
• Dhillon S. Certolizumab pegol: a review of its use in patients with axial spondyloarthritis or psoriatic arthritis. Drugs. 2014;74(9):999–1016.
   PubMed Web of Science ®Google Scholar
• Ueda, N., et al. The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factor alpha. Inflamm Bowel Dis. 2013;19(6):1224–1231.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Cimzia (certolizumab pegol): summary of product characteristics [Internet]. 2014 [cited 2016 Mar 3]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001037/WC500069763.pdf
   Google Scholar
• Sieper, J., et al. Impact of certolizumab pegol on patient-reported outcomes in patients with axial spondyloarthritis. Arthritis Care Res (Hoboken). 2015;67(10):1475–1480.
   PubMed Web of Science ®Google Scholar
• Van Der Heijde D, Maksymowych WP, Landewe RB, et al. Danuta, effect of certolizumab pegol on inflammation of spine and sacroiliac joints in patients with axial spondyloarthritis: 12 week magnetic resonance imaging results of a phase 3 double blind randomized placebo-controlled study [abstract no. 1705]. Arthritis Rheumatol. 2012;64(Suppl 10):S730.
   Google Scholar
• Van Der Heijde D, Braun J, Rudwaleit M, et al. Increased participation in daily activities after 24 weeks of certolizumab pegol treatment of axial spondyloarthritis patients, including patients with ankylosing spondylitis: results of a phase 3 double-blind randomized placebo-controlled study [abstract no. 1372]. Arthritis Rheumatol. 2012;64(Suppl 10):S592.
   Google Scholar
• Sieper, J., et al. Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trial. Arthritis Rheumatol. 2015;67(3):668–677.
   PubMed Web of Science ®Google Scholar
• Boonen, A., et al. Impact of ankylosing spondylitis on sick leave, presenteeism and unpaid productivity, and estimation of the societal cost. Ann Rheum Dis. 2010;69(6):1123–1128.
   PubMed Web of Science ®Google Scholar
• Boonen, A., et al. The burden of non-radiographic axial spondyloarthritis. Semin Arthritis Rheum. 2015;44(5):556–562.
   PubMed Web of Science ®Google Scholar
• Rudwaleit, M., et al. Observed incidence of uveitis following certolizumab pegol treatment in patients with axial spondyloarthritis. Arthritis Care Res (Hoboken). 2016;68(6):838–844.
   PubMed Web of Science ®Google Scholar
• Deodhar, A., et al. The concept of axial spondyloarthritis: joint statement of the spondyloarthritis research and treatment network and the assessment of spondyloarthritis international society in response to the US Food and drug administration’s comments and concerns. Arthritis Rheumatol. 2014;66(10):2649–2656.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Simponi (golimumab): summary of product characteristics [Internet]. 2014 [cited 2016 Mar 10]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000992/WC500052368.pdf
   Google Scholar
• Dougados, M., et al. Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2014;66(8):2091–2102.
   PubMed Web of Science ®Google Scholar
• Song, I.H., et al. Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1 year of treatment with etanercept: results from the ESTHER trial. Ann Rheum Dis. 2013;72(6):823–825.
   PubMed Web of Science ®Google Scholar
• Sieper, J., et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis. 2013;72(6):815–822.
   PubMed Web of Science ®Google Scholar
• Deodhar, A., et al. The term ‘non-radiographic axial spondyloarthritis’ is much more important to classify than to diagnose patients with axial spondyloarthritis. Ann Rheum Dis. 2016;75(5):791–794.
   PubMed Web of Science ®Google Scholar
• Sieper, J., et al. A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2015;67(10):2702–2712.
   PubMed Web of Science ®Google Scholar